Target intelligence / Profile preview

Bactericidal permeability-increasing protein (BPI)

Target
BPI
Molecular classification
Other (lipid-binding immune modulator), Pattern recognition molecule, Antimicrobial protein, Member of the tubular-lipid binding (TULIP) family
01

Overview

Bactericidal permeability-increasing protein (BPI) is a 55–60 kDa cationic protein predominantly found in the granules of human neutrophils, as well as in some epithelial cells[1][2]. It is a member of the TULIP (tubular lipid binding) family and exhibits potent antimicrobial activity, particularly against Gram-negative bacteria by binding to lipopolysaccharide (LPS), a component of their outer membrane[1][2]. BPI neutralizes LPS, reducing its endotoxic activity and associated inflammation, and can lead to bacterial cell death by damaging bacterial membranes[1][2]. The protein also plays a role in opsonization and facilitates the recognition and uptake of bacterial components by immune cells[1]. Structurally, BPI is divided into two domains: the amino-terminal region is highly cationic and responsible for bactericidal and LPS-binding activity, while the carboxy-terminal region contributes to opsonization and cell interactions[1][2]. Recent research has revealed that BPI also interacts with bacterial lipopeptides and lipoteichoic acids from Gram-positive bacteria, enhancing immune response—marking a role beyond Gram-negative defense[2]. BPI has anti-angiogenic properties, can bind vascular endothelial growth factor (VEGF), and modulate vascular and immune cell signaling pathways[1]. Therapeutic applications for recombinant BPI are being explored in infectious and inflammatory diseases, but its dual role as both neutralizer and enhancer (depending on the ligand and context) raises important safety and mechanistic considerations[1][2].

Other names
Bactericidal/permeability-increasing proteinBPIBPIFD1CAP 57BPI fold containing family D member 1recombinant BPI holoproteinrBPI
02

Mechanism of action

Binds and neutralizes LPS from Gram-negative bacteria; disrupts bacterial membranes leading to bactericidal effect; enhances or modulates immune response to bacterial lipopeptides and lipoteichoic acids in Gram-positive bacteria; inhibits LPS-induced inflammatory signaling; can modulate angiogenesis by binding VEGF

03

Biological functions

Innate immune responseBactericidal activity (mainly against Gram-negative bacteria)Lipopolysaccharide (LPS) neutralizationOpsonizationModulation of inflammationPattern recognitionAnti-angiogenic activityModulation of dendritic cell maturation
04

Disease associations

Infection (especially sepsis, meningitis)InflammationPotential role in cancer and atherosclerosis (via anti-angiogenic properties)Other (immune dysfunction, defense against Gram-negative and certain Gram-positive pathogens)
05

Safety considerations

Potential for pro-inflammatory enhancement in Gram-positive infectionsrisk of unintended modulation of immune responsesincomplete understanding of receptor interactions may complicate therapeutic development
06

Interacting drugs

Recombinant BPI derivatives (e.g., rBPI21, rBPI23) used in research and clinical trials; direct approved drugs targeting BPI not established
07

Biomarkers

BPI protein levels in plasma or cerebrospinal fluid (as biomarkers for infection severity, sepsis, bacterial meningitis, or innate immune activation)

Beyond the preview

Go deeper on Bactericidal permeability-increasing protein (BPI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bactericidal permeability-increasing protein (BPI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call